ZyVersa Therapeutics, Inc. (ZVSA)
2025-06-30 | ||||
|---|---|---|---|---|
| Income tax benefit | - | |||
| Change in fair value of equity payable | 37,149 | |||
| Research and development | 409,937 | |||
| General and administrative | 1,634,195 | |||
| Total operating expenses | 2,044,132 | |||
| Loss from operations | -2,044,132 | |||
| Interest expense | -130,036 | |||
| Pre-tax net loss | -2,211,317 | |||
| Net loss | -2,211,317 | |||
| Basic | -0.46 | |||
| Basic | 4,814,115 | |||
| Diluted | -0.46 | |||
| Diluted | 4,814,115 | |||